NCT00401479View on ClinicalTrials.gov

A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2006

Conditions
Irritable Bowel Syndrome (IBS)
Interventions
DRUG

Placebo

DRUG

Solabegron (GW427353)

Trial Locations (1)

55905

GSK Investigational Site, Rochester

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY